Search for a trial | Research with human participants

2 results

An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples in a first line setting from patients diagnosed with metastatic Colorectal Cancer (mCRC) to determine the KRAS G12C mutation status as part of the inclusion criteria into the Amgen Phase III clinical trial (Protocol No 20210081) to demonstrate clinical performance of the therascreen® KRAS RGQ PCR Kit.

Approved WMORecruiting will start

To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen*s Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical trial. Results of…

ENRICHED

Approved WMOPending

To compare the effect of a 6-month of enriched care consisting of additional protein intake and regular resistance exercise on the prevalence of disproportional fat-free mass loss (defined as a FFML/WL>30% as main outcome parameter) in…